Immuron Limited (IMRN) Investment Research Dashboard
About Immuron Limited (IMRN) stock analysis
Get live IMRN stock price $1.11, comprehensive Immuron Limited stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time IMRN stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activit...
Company Information
- CEO
- Steven George Lydeamore
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
Contact Information
- Website
- https://www.immuron.com.au
- Address
- 25-37 Chapman Street
- Country
- AU
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.50) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Immuron Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Immuron Limited
- ⚠Investors should consider how Immuron Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
7.15M
P/E Ratio (TTM)
-5.40
Beta
0.50
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
84/100 ⭐⭐⭐⭐⭐
- Overall
- +0.2%
- NYSE
- +0.7%
- NASDAQ
- -0.2%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.3% | +0.9% | +3.0% | 19.0 | 85/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.2% | +1.0% | +4.1% | 23.5 | 84/100⭐⭐⭐⭐⭐ |
| Real Estate | +1.8% | +2.1% | -0.3% | 29.7 | 72/100⭐⭐⭐⭐⭐ |
| Communication Services | +0.7% | -2.5% | +2.8% | 21.8 | 62/100⭐⭐⭐⭐ |
| Basic Materials | +0.9% | +0.4% | -1.3% | 24.9 | 55/100⭐⭐⭐⭐ |
| Consumer Defensive | +0.8% | -0.0% | -0.9% | 28.7 | 53/100⭐⭐⭐ |
| Utilities | -0.7% | +2.0% | -1.3% | 25.2 | 52/100⭐⭐⭐ |
| Energy | -0.2% | +0.4% | -2.4% | 19.6 | 49/100⭐⭐⭐ |
| Consumer Cyclical | +0.3% | -3.1% | -2.8% | 43.3 | 14/100⭐ |
| Technology | -1.6% | -0.3% | -3.1% | 42.2 | 14/100⭐ |
| Industrials | -0.5% | -1.3% | -8.9% | 30.4 | 10/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-26.